The analysis of nearly 2 million individuals confirmed that GLP-1 receptor agonists offer significant benefits for weight loss and other health issues, but with notable risks.
Some researchers argue that the study's conclusions regarding GLP-1 receptor agonists need more detail, stating, 'It is one thing for a benefit or harm to be 'associated' with use... it is another if it changes the risk a great deal.'
Dr. Ziyad Al-Aly emphasized, 'But no one had comprehensively investigated the effectiveness and risks of GLP-1 receptor agonists across all possible health outcomes,' underscoring the importance of this analysis.
Although there are newfound risks, including arthritis and pancreatitis linked to GLP-1 drugs, health professionals believe this data could guide real-world applications of these medications.
Collection
[
|
...
]